查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2040561

罕見疾病基因檢測市場規模、佔有率和趨勢分析報告：按疾病、技術、專業、最終用途、地區和細分市場預測（2026-2033 年）

Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report By Disease, By Technology, By Specialty, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

罕見疾病基因檢測市場概述

全球罕見疾病基因檢測市場預計到 2025 年價值 12.9315 億美元，預計到 2033 年將達到 38.8376 億美元。

預計從 2026 年到 2033 年，該市場將以 14.87% 的複合年成長率成長。推動該市場成長的因素包括次世代定序(NGS) 技術的進步、人們對罕見遺傳疾病的認知不斷提高以及對個人化醫療日益成長的需求。

此外，政府機構出於安全原因強制進行酒精和藥物檢測的嚴格規定，以及加強對藥物濫用的監測和打擊力度，預計將進一步推動市場成長。

罕見疾病患者登記庫的擴展和成熟正成為推動罕見疾病基因檢測市場成長的關鍵因素。這些登記庫系統地匯總表現型資料、縱向臨床病程、基因組定序結果和病患報告結局，從而建構了一個集中化、結構化的資料生態系統。透過將零散的臨床資訊轉化為一致的資料集，登記庫使臨床醫生和診斷實驗室能夠更有效地識別基因型-表現型相關性、改進突變解讀並提高診斷準確性。

鑑於罕見疾病的規模和複雜性（全球有超過3億人受其影響，光是美國就有約2500萬至3000萬名患者），這項進展尤其意義重大。儘管診斷技術不斷進步，但平均診斷時間仍超過六年，且僅約40%的患者最終獲得確診。此外，近80%的罕見疾病具有遺傳性，且約一半確診病例發生在兒童，因此迫切需要高效、準確的基因檢測解決方案。

基因測序成本的持續下降是推動罕見疾病基因檢測市場成長的另一個大因素。過去20年間，定序經歷了快速發展，從21世紀初每個基因組約30億美元的高昂成本，發展成為如今更經濟實惠的技術，預計到2025年每個基因組的成本將降至約200美元。這項成本的顯著降低得益於次世代定序技術的進步以及Illumina和Ultima Genomics等主要產業參與者之間日益激烈的競爭。

定序成本的降低意義深遠，遠不止於降低成本。它使檢查室能夠在擴大檢測規模的同時，投資改善整體診斷流程。在上游工程，檢查室正透過更快的萃取技術和更有效率的工作流程來提升檢體處理能力。在下游環節，他們正增加對先進生物資訊學的投資，包括自動變異檢測、連續重分析流程和整合臨床決策支援系統。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：罕見疾病基因檢測市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 罕見疾病基因檢測市場分析工具

第4章：罕見疾病基因檢測市場：疾病特異性估算與趨勢分析

  • 按疾病分類的市場佔有率（2025 年和 2033 年）
  • 全球罕見疾病基因檢測市場：疾病特異性展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 神經系統疾病
    • 免疫系統疾病
    • 血液疾病
    • 內分泌和代謝疾病
    • 癌症
    • 肌肉骨骼疾病
    • 心血管疾病
    • 皮膚病
    • 其他罕見疾病

第5章：罕見疾病基因檢測市場：依技術分類的估算與趨勢分析

  • 按技術分類的市場佔有率，2025 年和 2033 年
  • 全球罕見疾病基因檢測市場：依技術分類，展望未來
  • 市場規模、預測與趨勢分析，2021-2033年
    • 次世代定序
    • 陣列技術
    • 基於PCR的檢測
    • FISH
    • 桑格定序
    • 核型分析

第6章：罕見疾病基因檢測市場：依專業領域分類的估計與趨勢分析

  • 按專業領域分類的市場佔有率（2025 年和 2033 年）
  • 全球罕見疾病基因檢測市場：依專業領域及前景分類
  • 市場規模、預測與趨勢分析，2021-2033年
    • 分子遺傳學檢測
    • 生化遺傳檢測
    • 染色體基因檢測

第7章：罕見疾病基因檢測市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率，2025 年和 2033 年
  • 全球罕見疾病基因檢測市場：依最終用途分類的展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 研究機構和合約研究組織
    • 醫院和診所
    • 診斷檢查室

第8章：罕見疾病基因檢測市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 全球市場概述（按地區分類）
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 供應商情況
    • 主要銷售代理商和通路夥伴名單
    • Key customers
    • Key company market share analysis, 2025
    • Quest Diagnostics Inc.
    • Centogene NV
    • Invitae Corp.
    • 3billion, Inc.
    • Arup Laboratories
    • Eurofins Scientific
    • Strand Life Sciences
    • Ambry Genetics
    • Perkin Elmer, Inc.
    • Realm IDX, Inc.
    • Macrogen, Inc.
    • Baylor Genetics
    • Color Genomics, Inc.
    • Health Network Laboratories
    • PreventionGenetics
    • Progenity, Inc.
    • Coopersurgical, Inc.
    • Fulgent Genetics Inc.
    • Myriad Genetics, Inc.
    • Laboratory Corporation of America Holdings
    • Opko Health, Inc.
    • Artemis DNA
Product Code: GVR-4-68038-695-0

Rare Disease Genetic Testing Market Summary

The global rare disease genetic testing market size was estimated at USD 1,293.15 million in 2025 and is projected to reach USD 3,883.76 million by 2033, growing at a CAGR of 14.87% from 2026 to 2033. The market is driven by advancements in next-generation sequencing (NGS), increased awareness of rare genetic disorders, and rising demand for personalized medicine.

In addition, strict regulations from various government bodies requiring alcohol and substance testing for safety reasons, along with increased initiatives to monitor and address substance abuse, are anticipated to further enhance market growth.

The expansion and maturation of rare disease patient registries have emerged as a critical driver for the growth of the rare disease genetic testing market. These registries systematically aggregate phenotypic data, longitudinal clinical histories, genomic sequencing results, and patient-reported outcomes, thereby creating a centralized, structured data ecosystem. By transforming fragmented clinical information into cohesive datasets, registries enable clinicians and diagnostic laboratories to identify genotype-phenotype correlations more effectively, refine variant interpretation, and improve diagnostic accuracy.

This development is particularly significant given the scale and complexity of rare diseases, which affect over 300 million individuals globally, with approximately 25 to 30 million cases in the United States alone. Despite advances in diagnostics, the average diagnostic journey still exceeds six years, with only around 40% of patients receiving a confirmed diagnosis. Moreover, nearly 80% of rare diseases are genetic in origin, and about half of diagnosed cases occur in children, highlighting the urgent need for efficient and accurate genetic testing solutions.

The continuous decline in genome sequencing costs represents another major driver accelerating the growth of the rare disease genetic testing market. Over the past two decades, sequencing has evolved from an extremely expensive and time-intensive process-costing nearly USD 3 billion per genome in the early 2000s-to a highly accessible technology, with costs projected to reach approximately USD 200 per genome by 2025. This dramatic reduction has been driven by advances in next-generation sequencing technologies and by increasing competition among key industry players, such as Illumina and Ultima Genomics.

Lower sequencing costs have far-reaching implications beyond affordability. They enable laboratories to scale up testing volumes while simultaneously investing in improvements across the diagnostic workflow. On the upstream side, laboratories are enhancing sample processing capabilities through faster extraction techniques and streamlined workflows. Downstream, there is increased investment in advanced bioinformatics, including automated variant calling, continuous reanalysis pipelines, and integrated clinical decision support systems.

Global Rare Disease Genetic Testing Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rare disease genetic testing market report on the basis of disease, specialty, technology, end use and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Neurological Disorders
  • Immunological Disorders
  • Hematology Diseases
  • Endocrine & Metabolism Diseases
  • Cancer
  • Musculoskeletal Disorders
  • Cardiovascular Disorders
  • Dermatology Diseases
  • Other Rare Diseases
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Next Generation Sequencing
    • Whole Exome Sequencing
    • Whole Genome Sequencing
  • Array Technology
  • PCR-based Testing
  • FISH
  • Sanger Sequencing
  • Karyotyping
  • Specialty Outlook (Revenue, USD Million, 2021 - 2033)
  • Molecular Genetic Tests
  • Chromosomal Genetic Tests
  • Biochemical Genetic Tests
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Research Laboratories & CROs
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Specialty
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Specialty outlook
    • 2.2.3. Technology outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Rare Disease Genetic Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Expanding patient registry for rare disease
      • 3.2.1.2. Declining sequencing cost
      • 3.2.1.3. Technological advancements in disease diagnosis
      • 3.2.1.4. Launch of programs & new product development in rare disease diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Absence of effective diagnosis framework
      • 3.2.2.2. Technical challenges associated with genetic tests & data management
  • 3.3. Rare Disease Genetic Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Rare Disease Genetic Testing Market: Disease Estimates & Trend Analysis

  • 4.1. Disease Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Rare Disease Genetic Testing Market by Disease Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Neurological Disorders
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Immunological Disorders
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Hematology Diseases
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Endocrine & Metabolism Diseases
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Cancer
      • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Musculoskeletal Disorders
      • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. Cardiovascular Disorders
      • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8. Dermatology Diseases
      • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9. Other Rare Diseases
      • 4.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Rare Disease Genetic Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Rare Disease Genetic Testing Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Next Generation Sequencing
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 5.4.1.2. Whole Exome Sequencing
        • 5.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 5.4.1.3. Whole Genome Sequencing
        • 5.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Array Technology
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. PCR-based Testing
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. FISH
      • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.5. Sanger Sequencing
      • 5.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.6. Karyotyping
      • 5.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Rare Disease Genetic Testing Market: Specialty Estimates & Trend Analysis

  • 6.1. Specialty Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Rare Disease Genetic Testing Market by Specialty Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Molecular Genetic Tests
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Biochemical Genetic Tests
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Chromosomal Genetic Tests
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Rare Disease Genetic Testing Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2025 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Rare Disease Genetic Testing Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 7.4.1. Research Laboratories & CROs
      • 7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 7.4.2. Hospitals & Clinics
      • 7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 7.4.3. Diagnostic Laboratories
      • 7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD million)

Chapter 8. Rare Disease Genetic Testing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2025
    • 9.3.4. Quest Diagnostics Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Disease benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Centogene N.V.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Disease benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Invitae Corp.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Disease benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. 3billion, Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Disease benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Arup Laboratories
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Disease benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Eurofins Scientific
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Disease benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Strand Life Sciences
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Disease benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Ambry Genetics
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Disease benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Perkin Elmer, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Disease benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Realm IDX, Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Disease benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Macrogen, Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Disease benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Baylor Genetics
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Disease benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Color Genomics, Inc.
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Disease benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. Health Network Laboratories
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Disease benchmarking
      • 9.3.17.4. Strategic initiatives
    • 9.3.18. PreventionGenetics
      • 9.3.18.1. Company overview
      • 9.3.18.2. Financial performance
      • 9.3.18.3. Disease benchmarking
      • 9.3.18.4. Strategic initiatives
    • 9.3.19. Progenity, Inc.
      • 9.3.19.1. Company overview
      • 9.3.19.2. Financial performance
      • 9.3.19.3. Disease benchmarking
      • 9.3.19.4. Strategic initiatives
    • 9.3.20. Coopersurgical, Inc.
      • 9.3.20.1. Company overview
      • 9.3.20.2. Financial performance
      • 9.3.20.3. Disease benchmarking
      • 9.3.20.4. Strategic initiatives
    • 9.3.21. Fulgent Genetics Inc.
      • 9.3.21.1. Company overview
      • 9.3.21.2. Financial performance
      • 9.3.21.3. Disease benchmarking
      • 9.3.21.4. Strategic initiatives
    • 9.3.22. Myriad Genetics, Inc.
      • 9.3.22.1. Company overview
      • 9.3.22.2. Financial performance
      • 9.3.22.3. Disease benchmarking
      • 9.3.22.4. Strategic initiatives
    • 9.3.23. Laboratory Corporation of America Holdings
      • 9.3.23.1. Company overview
      • 9.3.23.2. Financial performance
      • 9.3.23.3. Disease benchmarking
      • 9.3.23.4. Strategic initiatives
    • 9.3.24. Opko Health, Inc.
      • 9.3.24.1. Company overview
      • 9.3.24.2. Financial performance
      • 9.3.24.3. Disease benchmarking
      • 9.3.24.4. Strategic initiatives
    • 9.3.25. Artemis DNA
      • 9.3.25.1. Company overview
      • 9.3.25.2. Financial performance
      • 9.3.25.3. Disease benchmarking
      • 9.3.25.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of abbreviation
  • Table 3 North America rare disease genetic testing market, by region, 2021 - 2033 (USD Million)
  • Table 4 North America rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 5 North America rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 6 North America rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 7 North America rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 8 U.S. rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 9 U.S. rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 10 U.S. rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 11 U.S. rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Canada rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 13 Canada rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 14 Canada rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 15 Canada rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Mexico rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 17 Mexico rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 18 Mexico rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Europe rare disease genetic testing market, by region, 2021 - 2033 (USD Million)
  • Table 21 Europe rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 22 Europe rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 23 Europe rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 24 Europe rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 25 Germany rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 26 Germany rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 27 Germany rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 28 Germany rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 29 UK rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 30 UK rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 31 UK rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 32 UK rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 33 France rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 34 France rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 35 France rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 36 France rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Italy rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 38 Italy rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 39 Italy rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 40 Italy rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Spain rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 42 Spain rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 43 Spain rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 44 Spain rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Denmark rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 46 Denmark rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 47 Denmark rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Denmark rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 49 Sweden rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 50 Sweden rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 51 Sweden rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Sweden rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 53 Norway rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 54 Norway rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 55 Norway rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 56 Norway rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific rare disease genetic testing market, by region, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 62 China rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 63 China rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 64 China rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 65 China rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 66 Japan rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 67 Japan rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 68 Japan rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 69 Japan rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 70 India rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 71 India rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 72 India rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 73 India rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 74 South Korea rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 75 South Korea rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 76 South Korea rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 77 South Korea rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 78 Australia rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 79 Australia rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 80 Australia rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 81 Australia rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Thailand rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 83 Thailand rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 84 Thailand rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 85 Thailand rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 86 Latin America rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 87 Latin America rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 88 Latin America rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 89 Latin America rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Brazil rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 91 Brazil rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 92 Brazil rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 93 Brazil rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 94 Argentina rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 95 Argentina rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 96 Argentina rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 97 Argentina rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 98 MEA rare disease genetic testing market, by region, 2021 - 2033 (USD Million)
  • Table 99 MEA rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 100 MEA rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 101 MEA rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 102 MEA rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 103 South Africa rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 104 South Africa rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 105 South Africa rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 106 South Africa rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 107 Saudi Arabia rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 111 UAE rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 112 UAE rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 113 UAE rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 114 UAE rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)
  • Table 115 Kuwait rare disease genetic testing market, by disease, 2021 - 2033 (USD Million)
  • Table 116 Kuwait rare disease genetic testing market, by specialty, 2021 - 2033 (USD Million)
  • Table 117 Kuwait rare disease genetic testing market, by technology, 2021 - 2033 (USD Million)
  • Table 118 Kuwait rare disease genetic testing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Pathology Laboratories market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Rare disease genetic testing market: Disease movement analysis
  • Fig. 12 Rare disease genetic testing market: Disease outlook and key takeaways
  • Fig. 13 Neurological Disorders market estimates and forecast, 2021 - 2033
  • Fig. 14 Immunological Disorders market estimates and forecast, 2021 - 2033
  • Fig. 15 Hematology Diseases market estimates and forecast, 2021 - 2033
  • Fig. 16 Endocrine & Metabolism Diseases market estimates and forecast, 2021 - 2033
  • Fig. 17 Cancer market estimates and forecast, 2021 - 2033
  • Fig. 18 Musculoskeletal Disorders market estimates and forecast, 2021 - 2033
  • Fig. 19 Cardiovascular Disorders market estimates and forecast, 2021 - 2033
  • Fig. 20 Dermatology Diseases market estimates and forecast, 2021 - 2033
  • Fig. 21 Other market estimates and forecast, 2021 - 2033
  • Fig. 22 Rare disease genetic testing market: Specialty movement Analysis
  • Fig. 23 Rare disease genetic testing market: Specialty outlook and key takeaways
  • Fig. 24 Molecular Genetic Tests market estimates and forecasts,2021 - 2033
  • Fig. 25 Chromosomal Genetic Tests market estimates and forecasts,2021 - 2033
  • Fig. 26 Biochemical Genetic Tests market estimates and forecasts, 2021 - 2033
  • Fig. 27 Rare disease genetic testing market: technology movement analysis
  • Fig. 28 Rare disease genetic testing market: technology outlook and key takeaways
  • Fig. 29 Next Generation Sequencing market estimates and forecasts, 2021 - 2033
  • Fig. 30 Whole Exome Sequencing market estimates and forecasts,2021 - 2033
  • Fig. 31 Whole Genome Sequencing market estimates and forecasts,2021 - 2033
  • Fig. 32 Array Technology market estimates and forecasts,2021 - 2033
  • Fig. 33 PCR-based Testing market estimates and forecasts, 2021 - 2033
  • Fig. 34 FISH market estimates and forecasts, 2021 - 2033
  • Fig. 35 Sanger Sequencing market estimates and forecasts, 2021 - 2033
  • Fig. 36 Karyotyping market estimates and forecasts, 2021 - 2033
  • Fig. 37 Rare disease genetic testing market: end use movement analysis
  • Fig. 38 Rare disease genetic testing market: end use outlook and key takeaways
  • Fig. 39 Research Laboratories & CROs market estimates and forecasts,2021 - 2033
  • Fig. 40 Hospitals & Clinics market estimates and forecasts,2021 - 2033
  • Fig. 41 Diagnostic Laboratories market estimates and forecasts,2021 - 2033
  • Fig. 42 Global rare disease genetic testing market: Regional outlook and key takeaways
  • Fig. 43 North America market estimates and forecasts, 2021 - 2033
  • Fig. 44 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 45 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 46 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 47 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 48 UK market estimates and forecasts, 2021 - 2033
  • Fig. 49 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 50 France market estimates and forecasts, 2021 - 2033
  • Fig. 51 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 52 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 53 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 54 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 55 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 56 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 57 China market estimates and forecasts, 2021 - 2033
  • Fig. 58 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 59 India market estimates and forecasts, 2021 - 2033
  • Fig. 60 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 61 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 62 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 63 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 64 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 65 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 66 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 67 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 68 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 69 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 70 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 71 Market share of key market players- rare disease genetic testing market